The Micro Cap Opportunity
Proven Strategies for the Astute Micro Cap & Nano Cap Stock Speculator
06/26/2008
The MCO Daily - Before the Bell for Friday June 27th, 2008
The Micro Cap Opportunity 'Daily'
‘Before the Bell’ for Friday, June 27th, 2008
On the Radar: LLSR, PSPM, SOLM, GLOB, VLNC, HYGS
This morning's top Micro Cap trading ideas include, Lantis Laser, Inc. (OTCPK: LLSR), Purespectrum, Inc. (OTCPK: PSPM), Solomon Technologies, Inc. (OTCBB: SOLM), Global, Med Technologies, Inc. (OTCBB: GLOB), Valence Technology, Inc. (NASD: VLNC), Hydrogenics Corp. (NASD: HYGS).
Featured Pick
LANTIS LASER, INC. (OTCPK: LLSR)
Up 0.00% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=LLSR.PK
Lantis was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 and Phase 3 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System(tm) in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); Lightlab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser (Pink Sheets:LLSR), visit www.lantislaser.com
Recent LLSR News:
June 26, 2008 - Lantis Laser's Dental Diagnostic Imaging System Can Address ADA's Recommendations for Placement of Sealants
Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com), wishes to draw attention to new, recently introduced, clinical recommendations from the American Dental Association Council on Scientific Affairs to assist clinicians in their decision-making process, for the use of composite plastic sealants over very early decay on the occlusal biting surface of teeth in children, adolescents and young adults to stop the disease from progressing.
"Placing sealants on the biting surfaces can stop early decay that is still in the enamel from progressing," pointed out Dr. Craig Gimbel, Executive Vice President of Clinical Affairs for Lantis Laser. "This article mentions that the clinician may be uncomfortable to make the decision to place a sealant because of unavailable adequate diagnostic tools for diagnosis and monitoring to ascertain if the sealant will be placed on top of existing decay in the enamel."
Dr. Gimbel went on to emphasize that, "Presently, the only accepted way to ascertain if decay is present is by recognition of tooth surface color changes, which can be misinterpreted as stains or defects instead of decay or possibly decay when it didn't exist at all." It is well documented that x-rays do not generally have the ability to image very early decay, which is important for the success of this procedure.
It is important to note that the ADA states that clinicians should not obtain radiographs for the sole purpose of placing sealants and should consult the ADA/U.S. Food and Drug Administration guidelines regarding selection criteria for dental radiographs which places limitations due to risk of radiation.
Lantis' OCT (Optical Coherence Tomography) Diagnostic Imaging System(tm) will assist the clinician in making an evidence-based decision to place the sealant because of its ability to image early decay and subsurface enamel changes which is indicative of the demineralization, the first stage in the process of decay.
In addition, it will enable the dentist to monitor the sealed tooth surface area in order to determine that this non surgical method of arresting the decay has been effective. Clinical studies have shown that Lantis' OCT Diagnostic Imaging System(tm) is the only dedicated dental imaging system that can provide evidence for early decay demineralization and then follow the process of remineralizing as the bacteria die under the placed sealant, all without the risk of radiation. The placement of sealants will enable patients to possibly avoid invasive dental procedures, such as fillings, that are associated with later stage decay.
Lantis' OCT Dental Imaging System(tm) is based on novel light-based, bio-medical imaging technology, Optical Coherence Tomography, that enables the dentist to do diagnostic imaging, chairside and in real-time. As the power source is light-based, unlike x-ray there is no harmful radiation. Images can be captured at a resolution of up to 10 times that of x-ray, enabling early detection of decay and detailed examination of microstructural defects.
PURESPECTRUM, INC. (OTCPK: PSPM)
Up 22.73% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=PSPM.PK
PureSpectrum (PINKSHEETS: PSPM) is a publicly traded technology company founded and headquartered in Savannah, Ga. The company's values are grounded in an awareness of the increasing urgency to identify more efficient energy solutions. PureSpectrum currently holds the rights to multiple patents and patent applications related to an electronic ballast design which would produce a soft switching environment during power conversion for artificial lighting. PureSpectrum will continue its commitment to researching, developing and refining ideas that will provide the most energy efficient, cost effective methods for powering artificial light. For more information on PureSpectrum, please call (912) 961-4980 or visit www.purespectrumlighting.com.
Recent PSPM News:
June 26, 2008 - PureSpectrum, Inc. Issued New Patent for High Frequency Electronic Ballast
PureSpectrum, Inc. (PINKSHEETS: PSPM) was recently awarded a full patent for a high frequency, high efficiency electronic ballast with a sine wave oscillator that further strengthens the company's patent portfolio.
The issuance of the patent is the latest demonstration of PureSpectrum's ongoing effort to reinforce corporate organization and infrastructure as the company prepares for expanded operations. PureSpectrum owns the rights to a family of patents and patent applications related to electronic ballast technology engineered to address both manufacturability and functionality. During the first two quarters of 2008 the company has been engaged in licensing discussions with multiple major lighting manufacturers regarding proprietary dimmable ballast circuitry for Compact Fluorescent Light (CFL) bulbs, linear fluorescent lamps as well as a proprietary design for a dimming device.
Patent 7,388,334 is one of multiple circuitry technologies identified by PureSpectrum which provide a diverse range of performance benefits for fluorescent lighting. The patent describes a high efficiency electronic ballast that is addressable to all gas discharge lighting applications.
As the company focuses on marketing the most recent iterations of its technology, PureSpectrum president and CEO Lee Vanatta said it is critical for the company to continue diligently protecting the base science which was the foundation for the company's technology breakthroughs. The issuance of patents also further strengthens PureSpectrum's position in ongoing licensing discussions with lighting manufacturers.
"We are firmly committed to protecting all aspects of PureSpectrum's intellectual property to ensure the most possible avenues for revenue generation and guarantee our shareholders that this company is thoroughly prepared for rapid growth," Vanatta said. "This patent represents our advance technology team's initial discoveries in properly controlling wave forms within the ballast to reduce the heat and energy losses in order to direct more power to the generation of light."
Go to www.purespectrumlighting.com or www.pinksheets.com for more information about PureSpectrum or to view PureSpectrum's full financial documentation through December 31, 2007. Call (912) 961-2980 with inquiries regarding PureSpectrum or PureSpectrum Technology.
SOLOMON TECHNOLOGIES, INC. (OTCBB: SOLM)
Up 37.50% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=SOLM.OB
Solomon Technologies, Inc., through its Motive Power and Power Electronics divisions, develops, licenses, manufactures and sells precision electric power drive systems, including those utilizing its patented Electric Wheel(R) Electric Transaxle(TM) and hybrid and regenerative technologies as well as direct current power supplies and power supply systems requiring high levels of reliability and ruggedness for defense, aerospace, marine, commercial, automotive, hybrid electric and all electric vehicle applications.
Recent SOLM News:
June 26, 2008 - Solomon Systems Commissioned in Singapore
Solomon Technologies, Inc. (OTC Bulletin Board: SOLM) today announced that the first eight water taxis using Solomon's ST-74 marine propulsion systems have been commissioned for operations in the rivers and harbor areas of Singapore. Solomon worked with the marine constructor in Singapore to provide a powerful, environmentally friendly system, using its proprietary propulsion technology.
Peter W. DeVecchis, President of Solomon commented, "We are pleased that the installation and operation of these systems went so smoothly. We designed them for simplicity of installation in remote environments without the need for factory assistance on-site. Our customer required very little guidance in installing and making the systems operational in record time." He continued, "We intentionally designed these products with the goal of having them operate almost universally, within certain power requirements, in various hull configurations, similar to the 'Plug & Play' concept in the electronics industry. We believe our product performance will lead to additional orders to complete the project."
GLOBAL MED TECHNOLOGIES, INC. (OTCBB: GLOB)
Up 18.10% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=GLOB.OB
Global Med Technologies(R), Inc. is an international e-Health medical information technology company providing information management software products and services to the healthcare industry. Its Wyndgate Technologies(R) division is a leading supplier of information management systems to U.S. and international blood centers and hospital transfusion centers. Each year, Wyndgate's products and services manage more than eight million blood components, representing over 27% of the U.S. blood supply. Wyndgate's products are also being used in Canada, Africa, and the Caribbean. Wyndgate's software provides Vein-to-Vein(R) tracking from donor collection to patient transfusion through its Donor Doc(TM) interactive donor health history questionnaire, ElDorado Donor(TM) and SafeTrace(R) donor management systems, to its SafeTrace Tx(R) advanced transfusion management system. Global Med's PeopleMed(R), Inc. subsidiary provides custom software validation, consulting and compliance solutions to hospitals and blood centers. PeopleMed's in-depth knowledge of Wyndgate's products and the blood banking industry results in cost-effective validation services, which leads to more efficient software implementations and upgrades for our customers.
Recent GLOB News:
June 26, 2008 - Global Med Technologies(R), Inc. Completes Acquisition of Inlog, SA, a Leading European Medical Software Firm
Global Med Technologies(R), Inc. ("Global Med" or the "Company") (OTC Bulletin Board: GLOB), an international e-Health, medical information technology company, today announced the completed acquisition of Inlog, SA, and its German and related subsidiary ("Inlog"), a private European medical software firm, for a maximum of $11.5 million in a combination of cash, stock and earnout. The structure of this transaction is expected to be accretive, exclusive of financing costs, in the first full year of operations. Inlog's management is planning to stay with the Company.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO)
Inlog, based in Lyon, France, with additional operations in Grenoble, France, and Munich and Alzey, Germany, is a leading European provider of donor center and transfusion information management systems as well as laboratory information systems and other ancillary medical software systems. Inlog currently maintains 700 sites in 15 countries.
Inlog's shareholders must use $500,000 of the cash proceeds to purchase Global Med common stock in the open market within three months of the closing. Inlog's unaudited revenues for their fiscal year ended June 30, 2007 were approximately euro 7.0 million* or about $12.4 million at current exchange rates, with EBITDA of approximately euro 940,000* or approximately $1.45 million. Inlog's unaudited revenues for the nine months ended March 31, 2008 were approximately euro 6.6 million or about $10.2 million at current exchange rates, with EBITDA of approximately euro 780,000 or approximately $1.2 million. Global Med will utilize a combination of existing cash and debt to pay for the transaction.
Chairman and CEO of Global Med Technologies, Inc., Michael I. Ruxin, M.D., stated, "The acquisition of Inlog by Global Med is a transforming event in the history of our Company. As a leading provider of blood and laboratory software applications in 20 countries (in the U.S., Canada, Caribbean, European Union, Africa, French Polynesia, and New Caledonia) we are now poised to grow our Company in the global marketplace and react quickly to a rapidly changing international market." Dr. Ruxin continued, "The accretive nature of the transaction will also further strengthen Global Med's financial position and propel the Company to develop more next-generation medical software solutions." Dr. Ruxin further stated, "With the combination of Global Med and Inlog, we know of no other company, domestic or international, that brings the breadth and depth of blood-related software applications to the world market. Our new international suite of software products contains eleven applications that will permit us to grow our global presence."
Interest has been generated on both sides of the Atlantic for products from Inlog and Global Med's U.S.-based division, Wyndgate Technologies. Particular notice has been shown by U.S. institutions for Inlog's EdgeCell software, a Cellular Therapy application for tissue banks, stem cell centers and cord blood centers. EdgeCell has received the European designation, NF/ISO 25051/12119 certification, assuring the highest level of quality regarding the design, the testing and validation of the software, the documentation quality and the quality of support and maintenance.
Inlog's product line also includes EdgeBlood** (also known as CTS Serveur, for the donor center marketplace), EdgeTrack** (for the hospital transfusion marketplace), EdgeLab (Laboratory Information System "LIS"), and SAPA (supports regulatory compliance and document management). Inlog is ISO 9001:2000 certified and these products have also received the NF/ISO 25051/12119 certification.
Inlog has a substantial blood center and transfusion market share in France, Germany, Austria, Belgium and Switzerland and installations in Greece and Monaco. In Africa, Inlog supplies its blood center and transfusion systems to the National Blood Services of Gabon, Burkina Faso and Senegal, as well as having installations in Algeria, the Ivory Coast and Rwanda. Inlog's EdgeLab, with 130 laboratory sites in France, is gaining market share in Germany, Spain, Belgium, the Middle East and Asia. There are no current plans to bring EdgeLab into the U.S.
Thomas F. Marcinek, the Company's President and COO, stated, "We are excited to have Inlog join the Global Med group of companies. As Inlog has significantly grown their market share, this acquisition doubles our customer base. Inlog's experience in handling international implementations and their cutting edge software solutions complement our current offerings and expand Global Med's market presence. Furthermore, EdgeCell, Inlog's successful cellular therapy software, will fulfill an immediate need for our customers in the U.S. market." Mr. Marcinek added, "We have respect and admiration for the Inlog management and staff and their attention to customer service. The synergistic value of bringing two strong organizations together will result in innovative solutions and continued dynamic growth."
Renaud Blanc-Bernard of Inlog commented, "On behalf of Inlog, we are all very pleased to join forces with Global Med. Becoming an international group of almost 200 people, present in 20 countries and maintaining 1,400 transfusion centers, blood banks and laboratories, we're developing our human, commercial and technical strengths while providing the capacity to handle large national implementations anywhere in the world." Mr. Blanc-Bernard further stated, "With the synergies between our two companies, we have now more than doubled the development capabilities of Global Med and are already seeing increased interest in our collective systems in the international marketplace. Our inaugural joint marketing efforts at the ISBT international conference in Macao, China were well received. We were also quite pleased at the interest shown in our products during a recent conference in the United States and we recognize the strategic advantages in providing an enhanced product line to customers."
VALENCE TECHNOLOGIES, INC. (NASD: VLNC) Up 19.44% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=VLNC
Valence developed and markets the industry's first commercially available, safe, large-format family of lithium phosphate rechargeable batteries. Valence holds an extensive, worldwide portfolio of issued and pending patents relating to its lithium phosphate rechargeable batteries. The company has facilities in Austin, Texas; Las Vegas, Nevada; Mallusk, Northern Ireland and Suzhou, China. Valence is traded on the NASDAQ Capital Market under the ticker symbol VLNC and can be found on the internet at www.valence.com.
Recent VLNC News:
June 26, 2008 - Valence Technology Receives Qualified Opinion from Its Auditors
Valence Technology, Inc. (NASDAQ:VLNC) today reported that, with respect to the financial statements included in the company's Annual Report on Form 10-K for the fiscal year ended March 31, 2008, the audit opinion of PMB Helin Donovan, LLP, the company's independent registered public accounting firm, contained a "going concern" qualification. The company also received a "going concern" qualification for the fiscal year ended March 31, 2007.
NASDAQ Marketplace Rule 4350(b)(1)(B) requires NASDAQ-listed companies to publicly announce through the news media the receipt of an audit opinion containing a "going concern" qualification. This announcement does not represent any change or amendment to the company's fiscal year 2008 financial statements, the Annual Report on Form 10-K, or to any statements made during the company's June 5, 2008 conference call to discuss its fiscal 2008 and fourth quarter financial results.
The Company's Annual Report on Form 10-K is available from the SEC's website at www.sec.gov.
HYDROGENICS CORP. (NASD: HYGS)
Up 10.34% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=HYGS
Hydrogenics Corporation (www.hydrogenics.com) is a globally recognized developer and provider of hydrogen generation and fuel cell products and services, serving the growing industrial and clean energy markets of today and tomorrow. Based in Mississauga, Ontario, Canada, Hydrogenics has operations in North America, Europe and Asia.
Recent HYGS News:
June 26, 2008 - Hydrogenics Provides Clean Energy Hydrogen Generation System to Shell-Hydrogen for California Hydrogen Highway
Hydrogenics Corporation (TSX: HYG) (NASDAQ: HYGS), a leading designer and manufacturer of hydrogen electrolyzers and fuel cell systems, today announced that it has provided an integrated hydrogen generation system to Shell Hydrogen LLC. The fueling station, which opened today in Los Angeles as part of California's Hydrogen Highway initiative, will generate hydrogen on site to service the increasing demands of hydrogen-powered consumer vehicles.
Hydrogenics provided an integrated hydrogen fueling station, based on its highly modular standard product line, including electrolyzer, compressor, storage, and dispensing systems. In order to meet the demanding space requirements of the fueling station, Hydrogenics implemented a canopy system where all the components are mounted on the roof of the station canopy, minimizing the footprint of the hydrogen station. In addition, Hydrogenics' electrolyzers produce hydrogen from water, providing the most environmentally friendly approach to hydrogen generation.
California is the most developed state in the U.S.A. in terms of Hydrogen energy, reflected by Governor Swartzeneger's promise of 200 Hydrogen refueling stations in California before he retires. "The experience gained in our 50-year history positions Hydrogenics to meet the rapid growth of the Hydrogen highway," said Daryl Wilson, President and CEO of Hydrogenics. "Our modular product offering is highly scaleable and configurable to meet widely varying requirements," added Wilson. Hydrogenics has installed over 30 fueling stations deriving hydrogen through electrolysis, which is the most environmentally friendly approach to hydrogen generation.
